Capital World Investors Has $233.49 Million Stake in Align Technology, Inc. (NASDAQ:ALGN)

Capital World Investors grew its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 0.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,119,784 shares of the medical equipment provider’s stock after purchasing an additional 515 shares during the quarter. Capital World Investors owned about 1.50% of Align Technology worth $233,486,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in ALGN. Picton Mahoney Asset Management raised its stake in shares of Align Technology by 69.9% in the fourth quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Align Technology in the 4th quarter worth approximately $31,000. Aster Capital Management DIFC Ltd acquired a new position in Align Technology during the 4th quarter worth $35,000. Private Trust Co. NA lifted its holdings in Align Technology by 113.4% during the 4th quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 93 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in Align Technology by 212.2% in the 4th quarter. Versant Capital Management Inc now owns 231 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 157 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Jefferies Financial Group cut their price target on Align Technology from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Mizuho reduced their target price on shares of Align Technology from $295.00 to $250.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC reissued a “hold” rating on shares of Align Technology in a research note on Thursday, February 6th. Wells Fargo & Company assumed coverage on shares of Align Technology in a research note on Friday, February 14th. They issued an “overweight” rating and a $255.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Align Technology from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.90.

Align Technology Stock Up 2.5 %

ALGN opened at $171.41 on Monday. The stock has a market cap of $12.55 billion, a P/E ratio of 30.55, a P/E/G ratio of 2.24 and a beta of 1.73. Align Technology, Inc. has a 12 month low of $141.74 and a 12 month high of $327.49. The company has a fifty day simple moving average of $172.70 and a 200 day simple moving average of $204.33.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%. On average, equities research analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.